Fundamental Analysis of THERIVA BIOLOGICS INC(NYSEARCA:TOVX) stock

Fundamental Rating

Overall TOVX gets a fundamental rating of 1 out of 10. We evaluated TOVX against 565 industry peers in the Biotechnology industry. TOVX may be in some trouble as it scores bad on both profitability and health. TOVX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

TOVX had negative earnings in the past year.

TOVX had a negative operating cash flow in the past year.

TOVX had negative earnings in each of the past 5 years.

TOVX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TOVX has a Return On Assets of -52.53%. This is comparable to the rest of the industry: TOVX outperforms 45.99% of its industry peers.

TOVX has a Return On Equity of -80.55%. This is comparable to the rest of the industry: TOVX outperforms 51.34% of its industry peers.

		Industry Rank	Sector Rank
ROA	-52.53%
ROE	-80.55%
ROIC	N/A

ROA(3y)-31.35%

ROA(5y)-67.33%

ROE(3y)-39.46%

ROE(5y)-77.34%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TOVX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for TOVX has been increased compared to 1 year ago.

The number of shares outstanding for TOVX has been increased compared to 5 years ago.

The debt/assets ratio for TOVX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -11.76, we must say that TOVX is in the distress zone and has some risk of bankruptcy.

TOVX's Altman-Z score of -11.76 is on the low side compared to the rest of the industry. TOVX is outperformed by 78.43% of its industry peers.

TOVX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

TOVX has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: TOVX outperforms 47.77% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-11.76

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.88 indicates that TOVX has no problem at all paying its short term obligations.

The Current ratio of TOVX (2.88) is worse than 66.13% of its industry peers.

TOVX has a Quick Ratio of 2.88. This indicates that TOVX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.88, TOVX is doing worse than 64.17% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.88
Quick Ratio	2.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TOVX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.87%.

EPS 1Y (TTM)7.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-26.12%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

TOVX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.43% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y7.59%

EPS Next 2Y16.4%

EPS Next 3Y13.43%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TOVX. In the last year negative earnings were reported.

Also next year TOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

TOVX's earnings are expected to grow with 13.43% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.4%

EPS Next 3Y13.43%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TOVX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (11/21/2024, 8:04:00 PM)

After market: 1.2501 -0.03 (-2.34%)

1.28

+0.02 (+1.59%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.91M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-52.53%
ROE	-80.55%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.88
Quick Ratio	2.88
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)7.87%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y7.59%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

THERIVA BIOLOGICS INC (TOVX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens